• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Capillarized 肝窦和细胞外基质屏障的顺序纳米穿透器用于肝纤维化治疗。

Sequential Nano-Penetrators of Capillarized Liver Sinusoids and Extracellular Matrix Barriers for Liver Fibrosis Therapy.

机构信息

State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea.

出版信息

ACS Nano. 2022 Sep 27;16(9):14029-14042. doi: 10.1021/acsnano.2c03858. Epub 2022 Aug 29.

DOI:10.1021/acsnano.2c03858
PMID:36036898
Abstract

During liver fibrogenesis, liver sinusoidal capillarization and extracellular matrix (ECM) deposition construct dual pathological barriers to drug delivery. Upon capillarization, the vanished fenestrae in liver sinusoidal endothelial cells (LSECs) significantly hinder substance exchange between blood and liver cells, while excessive ECM further hinders the delivery of nanocarriers to activated hepatic stellate cells (HSCs). Herein, an efficient nanodrug delivery system was constructed to sequentially break through the capillarized LSEC barrier and the deposited ECM barrier. For the first barrier, LSEC-targeting and fenestrae-repairing nanoparticles (named HA-NPs/SMV) were designed on the basis of the modification with hyaluronic acid and the loading of simvastatin (SMV). For the second barrier, collagenase I and vitamin A codecorated nanoparticles with collagen-ablating and HSC-targeting functions (named CV-NPs/siCol1α1) were prepared to deliver siCol1α1 with the goal of inhibiting collagen generation and HSC activation. Our results showed that upon encountering the capillarized LSEC barrier, HA-NPs/SMV rapidly released SMV and exerted a fenestrae-repairing function, which allowed more CV-NPs/siCol1α1 to enter the space of Disse to degrade deposited collagen and finally to achieve higher accumulation in activated HSCs. Scanning electronic microscopy images showed the recovery of liver sinusoids, and analysis of liver tissue sections demonstrated that HA-NPs/SMV and CV-NPs/siCol1α1 had a synergetic effect. Our pathological barrier-normalization strategy provides an antifibrotic therapeutic regimen.

摘要

在肝纤维化过程中,肝窦毛细血管化和细胞外基质(ECM)沉积构建了双重的药物传递病理屏障。在毛细血管化后,肝窦内皮细胞(LSEC)中消失的窗孔显著阻碍了血液和肝细胞之间的物质交换,而过多的 ECM 进一步阻碍了纳米载体向活化的肝星状细胞(HSCs)的传递。在此,构建了一种有效的纳米药物传递系统,以顺序突破毛细血管化的 LSEC 屏障和沉积的 ECM 屏障。对于第一个屏障,基于透明质酸修饰和辛伐他汀(SMV)装载,设计了 LSEC 靶向和窗孔修复纳米颗粒(命名为 HA-NPs/SMV)。对于第二个屏障,制备了具有胶原酶 I 和维生素 A 共载的具有胶原消融和 HSC 靶向功能的纳米颗粒(命名为 CV-NPs/siCol1α1),以递送 siCol1α1,目的是抑制胶原生成和 HSC 活化。我们的结果表明,遇到毛细血管化的 LSEC 屏障后,HA-NPs/SMV 迅速释放 SMV 并发挥窗孔修复功能,使更多的 CV-NPs/siCol1α1 进入 Disse 间隙降解沉积的胶原,最终在活化的 HSCs 中实现更高的积累。扫描电子显微镜图像显示肝窦恢复,肝组织切片分析表明 HA-NPs/SMV 和 CV-NPs/siCol1α1 具有协同作用。我们的病理屏障正常化策略提供了一种抗纤维化治疗方案。

相似文献

1
Sequential Nano-Penetrators of Capillarized Liver Sinusoids and Extracellular Matrix Barriers for Liver Fibrosis Therapy.Capillarized 肝窦和细胞外基质屏障的顺序纳米穿透器用于肝纤维化治疗。
ACS Nano. 2022 Sep 27;16(9):14029-14042. doi: 10.1021/acsnano.2c03858. Epub 2022 Aug 29.
2
Collagenase Type I and Probucol-Loaded Nanoparticles Penetrate the Extracellular Matrix to Target Hepatic Stellate Cells for Hepatic Fibrosis Therapy.Ⅰ型胶原酶和丙丁酚载药纳米颗粒穿透细胞外基质,靶向肝星状细胞,用于肝纤维化治疗。
Acta Biomater. 2024 Feb;175:262-278. doi: 10.1016/j.actbio.2023.12.027. Epub 2023 Dec 21.
3
Neutrophil-Based Bionic Delivery System Breaks Through the Capillary Barrier of Liver Sinusoidal Endothelial Cells and Inhibits the Activation of Hepatic Stellate Cells.基于中性粒细胞的仿生递药系统突破肝窦内皮细胞的毛细血管屏障并抑制肝星状细胞的活化。
Mol Pharm. 2024 Apr 1;21(4):2043-2057. doi: 10.1021/acs.molpharmaceut.4c00173. Epub 2024 Mar 12.
4
Engineered liposomes targeting hepatic stellate cells overcome pathological barriers and reverse liver fibrosis.靶向肝星状细胞的工程化脂质体克服病理障碍并逆转肝纤维化。
J Control Release. 2024 Apr;368:219-232. doi: 10.1016/j.jconrel.2024.02.022. Epub 2024 Feb 28.
5
Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.胶原酶 I 修饰的共递送胶束增强细胞外基质降解和肝星状细胞靶向治疗肝纤维化。
Acta Biomater. 2022 Oct 15;152:235-254. doi: 10.1016/j.actbio.2022.08.065. Epub 2022 Sep 8.
6
Restoration of Sinusoid Fenestrae Followed by Targeted Nanoassembly Delivery of an Anti-Fibrotic Agent Improves Treatment Efficacy in Liver Fibrosis.恢复肝血窦窗孔并随后靶向纳米组装递送抗纤维化药物可提高肝纤维化的治疗效果。
Adv Mater. 2023 Apr;35(17):e2212206. doi: 10.1002/adma.202212206. Epub 2023 Mar 14.
7
Capillarized Liver Sinusoidal Endothelial Cells Undergo Partial Endothelial-Mesenchymal Transition to Actively Deposit Sinusoidal ECM in Liver Fibrosis.毛细血管化的肝窦内皮细胞经历部分内皮-间充质转化,以在肝纤维化中积极沉积窦状细胞外基质。
Front Cell Dev Biol. 2021 Jul 5;9:671081. doi: 10.3389/fcell.2021.671081. eCollection 2021.
8
Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy.细胞外基质穿透纳米钻胶束用于肝纤维化治疗。
Biomaterials. 2020 Feb;230:119616. doi: 10.1016/j.biomaterials.2019.119616. Epub 2019 Dec 6.
9
Adipocyte Fatty Acid Binding Protein Promotes the Onset and Progression of Liver Fibrosis via Mediating the Crosstalk between Liver Sinusoidal Endothelial Cells and Hepatic Stellate Cells.脂肪细胞脂肪酸结合蛋白通过介导肝窦内皮细胞和肝星状细胞之间的串扰促进肝纤维化的发生和进展。
Adv Sci (Weinh). 2021 Jun;8(11):e2003721. doi: 10.1002/advs.202003721. Epub 2021 Mar 27.
10
Delta-like ligand 4/DLL4 regulates the capillarization of liver sinusoidal endothelial cell and liver fibrogenesis.Delta 样配体 4(DLL4)调控肝窦内皮细胞的毛细血管化和肝纤维化。
Biochim Biophys Acta Mol Cell Res. 2019 Oct;1866(10):1663-1675. doi: 10.1016/j.bbamcr.2019.06.011. Epub 2019 Jun 21.

引用本文的文献

1
Extracellular Matrix Signaling Cues: Biological Functions, Diseases, and Therapeutic Targets.细胞外基质信号线索:生物学功能、疾病及治疗靶点
MedComm (2020). 2025 Jul 17;6(8):e70281. doi: 10.1002/mco2.70281. eCollection 2025 Aug.
2
Extracellular vesicles targeting non-parenchymal cells: the therapeutical effect on liver fibrosis.靶向非实质细胞的细胞外囊泡:对肝纤维化的治疗作用
eGastroenterology. 2024 Mar 19;2(1):e100040. doi: 10.1136/egastro-2023-100040. eCollection 2024 Jan.
3
Pathological Microenvironment-Remodeling Nanoparticles to Alleviate Liver Fibrosis: Reversing Hepatocytes-Hepatic Stellate Cells Malignant Crosstalk.
用于缓解肝纤维化的病理微环境重塑纳米颗粒:逆转肝细胞-肝星状细胞的恶性串扰
Adv Sci (Weinh). 2025 Jan;12(4):e2408898. doi: 10.1002/advs.202408898. Epub 2024 Oct 28.
4
Liver cirrhosis: molecular mechanisms and therapeutic interventions.肝硬化:分子机制与治疗干预措施
MedComm (2020). 2024 Sep 17;5(10):e721. doi: 10.1002/mco2.721. eCollection 2024 Oct.
5
Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis.纳米医学在肝纤维化治疗中的应用的最新进展。
Beilstein J Nanotechnol. 2024 Aug 23;15:1105-1116. doi: 10.3762/bjnano.15.89. eCollection 2024.
6
Hepatic microcirculatory disturbance in liver diseases: intervention with traditional Chinese medicine.肝脏疾病中的肝微循环障碍:中医药干预
Front Pharmacol. 2024 Jul 23;15:1399598. doi: 10.3389/fphar.2024.1399598. eCollection 2024.
7
Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis.用于肝纤维化诊断的非侵入性分子成像探针的进展
Biomater Res. 2024 Jul 1;28:0042. doi: 10.34133/bmr.0042. eCollection 2024.
8
Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease.肝窦内皮细胞在代谢相关脂肪性肝病中的作用。
Cell Commun Signal. 2024 Jun 28;22(1):346. doi: 10.1186/s12964-024-01720-9.
9
Reactive Oxygen Species-Responsive Nanoparticles Toward Extracellular Matrix Normalization for Pancreatic Fibrosis Regression.活性氧响应纳米颗粒对细胞外基质的正常化作用,以促进胰腺纤维化的消退。
Adv Sci (Weinh). 2024 May;11(19):e2401254. doi: 10.1002/advs.202401254. Epub 2024 Mar 14.
10
Liver sinusoidal endothelial cells as potential drivers of liver fibrosis (Review).肝窦内皮细胞作为肝纤维化的潜在驱动因素(综述)。
Mol Med Rep. 2024 Mar;29(3). doi: 10.3892/mmr.2024.13164. Epub 2024 Jan 19.